Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2014 | 12-2013 | 12-2012 | 12-2011 | 12-2010 | |
| Sales | 19,615,600 | 23,113,100 | 22,603,400 | 24,286,500 | 23,076,000 |
| Cost of Goods | 4,932,500 | 4,908,100 | 4,796,500 | 5,067,900 | 4,366,200 |
| Gross Profit | 14,683,100 | 18,205,000 | 17,806,900 | 19,218,600 | 18,709,800 |
| Operating Expenses | 12,023,800 | 12,834,700 | 13,073,200 | 13,691,000 | 12,179,800 |
| Operating Income | 2,659,801 | 5,370,400 | 4,734,201 | 5,528,500 | 6,530,199 |
| Other Income | 340,499 | 518,900 | 673,999 | -179,000 | -4,999 |
| Pre-tax Income | 3,000,300 | 5,889,300 | 5,408,200 | 5,349,500 | 6,525,200 |
| Income Tax | 609,800 | 1,204,500 | 1,319,600 | 1,001,800 | 1,455,700 |
| Net Income Continuous | 2,390,500 | 4,684,800 | 4,088,600 | 4,347,700 | 5,069,500 |
| Net Income | $2,390,500 | $4,684,800 | $4,088,600 | $4,347,700 | $5,069,500 |
| EPS Basic Total Ops | 2.23 | 4.33 | 3.67 | 3.90 | 4.58 |
| EPS Basic Continuous Ops | 2.23 | 4.33 | 3.67 | 3.90 | 4.58 |
| EPS Diluted Total Ops | 2.23 | 4.32 | 3.66 | 3.90 | 4.58 |
| EPS Diluted Continuous Ops | 2.23 | 4.32 | 3.66 | 3.90 | 4.58 |
| EBITDA(a) | $4,038,801 | $6,816,000 | $6,196,401 | $6,902,100 | $7,858,399 |